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Good Life with osteoArthritis in Denmark
(GLA:D™): evidence-based education and
supervised neuromuscular exercise
delivered by certified physiotherapists
nationwide
Søren T. Skou1,2* and Ewa M. Roos1
Abstract
Background: The uptake of evidence-based guidelines in clinical practice is suboptimal in osteoarthritis (OA) and
other chronic diseases. Good Life with osteoArthritis in Denmark (GLA:D) was launched in 2013 with the aim of
implementing guidelines for the treatment of knee and hip OA in clinical care nationwide. The purpose of this
report was to evaluate the effects of the GLA:D intervention from 2013 to 2015, using data from the national GLA:D
registry.
Methods: Patients undergo education and supervised exercise delivered by trained physiotherapists. Outcomes
evaluated at baseline, 3 and 12 months are pain intensity (0 to 100, best to worst), objective physical function (30-s
chair-stand test and 40-m fast-paced walk test), physical activity (number of days per week being physically active
for at least 30 min), quality of life (Knee injury and Osteoarthritis Outcome Score (KOOS) and the Hip disability and
Osteoarthritis Outcome Score (HOOS) quality of life subscale, 0–100, worst to best), number of patients on
painkillers and sick leave, and access to care according to guidelines.
Results: Data from 9,825 participants from the GLA:D registry were utilised in the analyses. It was demonstrated
that GLA:D improved pain intensity and quality of life by 12.4 points and 5.4 points at 3 months, and 13.7 points
and 9.4 points at 12 months, respectively. Furthermore, physical function and physical activity improved (only at
3 months), fewer patients took painkillers following the treatment, and fewer patients were on sick leave at
12 months following GLA:D compared with the year prior to GLA:D. GLA:D is offered in all five health care regions
in Denmark via 286 active GLA:D units, but the uptake in the Danish municipalities is still low with only 20% of the
municipalities offering GLA:D.
Conclusion: Three years after its inception, GLA:D has been rolled out nationwide and has a significant impact not
only on patient symptoms and physical function, but also on intake of painkillers and sick leave. The lifestyle
changes introduced by education and supervised exercise were largely maintained at 1 year and may have the
potential to also improve general health and reduce societal costs.
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Background
Chronic diseases such as osteoarthritis (OA), type 2 dia-
betes, chronic obstructive pulmonary disease and low
back pain are highly prevalent and among the leading
causes of global disability [1]. These chronic diseases
often occur concurrently, making care more complex [2]
and potentially leading to worse disability for the indi-
vidual [3]. An under-appreciated cause of several chronic
diseases is physical inactivity [4]. As such, physical activ-
ity and exercise represent important components of pri-
mary prevention of at least 35 chronic diseases [4].
Furthermore, substantial evidence supports exercise as
first line treatment for a range of chronic diseases, in-
cluding musculoskeletal disorders [5, 6]. However, des-
pite the evidence, physical activity and exercise are
under-prescribed in the treatment of chronic diseases,
resulting in suboptimal care [7–9].
This is also true for OA. Despite strong evidence from
more than 50 randomised, controlled trials (RCTs) in
knee OA [10] and 10 RCTs in hip OA [11] supporting
the efficacy of exercise, and international guidelines
recommending it [12, 13], the uptake of exercise, educa-
tion and weight loss as first line treatment for patients
with painful knee and hip OA is suboptimal in clinical
practice [9]. A recent systematic review demonstrated
that only 36% of patients with OA received appropriate
non-pharmacological care according to the guidelines
[9]. Research highlights that the successful implementa-
tion of evidence in clinical practice requires a compre-
hensive approach adapted to the specific setting and
stakeholders and designed to address barriers to imple-
mentation [14].
Good Life with osteoArthritis in Denmark (GLA:D)
was initiated in January 2013 with the overarching aim
of implementing clinical guidelines for the treatment of
knee and hip OA in clinical practice in order to facilitate
high quality care of patients with OA in the Danish
population [15]. GLA:D consists of three mandatory ele-
ments: a 2-day course for physiotherapists; 8 weeks of
education and supervised neuromuscular exercise for
patients with knee and hip OA symptoms delivered by a
trained physiotherapist in clinical practice; and the na-
tional GLA:D registry with data from baseline, 3 and
12 months. The feasibility and short- and long-term im-
provements in symptoms from GLA:D has previously
been demonstrated in a pilot study [16, 17]; however, an
evaluation of the effects from GLA:D from a nationwide
perspective is lacking.
The purpose of this paper was to evaluate the specific
aims of the GLA:D initiative in patients with knee and
hip OA. The specific aims are reduced pain, reduced
number of patients taking pain killers, improved physical
function and physical activity, improved quality of life,
and reduced number of patients on sick leave. We also
wanted to evaluate the equality of access to care, accord-
ing to the guidelines across health care sectors and geo-
graphic regions in Denmark.
Methods
Design
This was a registry-based study evaluating the results
from the GLA:D initiative.
Ethics approval was not needed, according to the local
ethics committee of the North Denmark Region and nei-
ther was clinical trial registration, as it was a register-
based study and not a clinical trial. The GLA:D registry
was approved by the Danish Data Protection Agency
and all patients consented to submitting data to the
GLA:D registry.
Good Life with osteoArthritis in Denmark (GLA:D™)
GLA:D is a non-profit initiative hosted at the University
of Southern Denmark. The trademark has been regis-
tered to ensure that the quality of care is maintained at
a high level, since physiotherapists educated in GLA:D
are obliged to follow the principles of GLA:D and con-
tribute data to the national GLA:D registry.
Course for physiotherapists
Physiotherapists interested in GLA:D participate in a
2-day course giving them the requisite skills to diag-
nose OA and deliver OA care as described in the
clinical guidelines. The course comprises existing evi-
dence on OA and treatment of OA and a thorough
introduction to GLA:D, as well as practical instruc-
tions in the specific protocol of GLA:D, including de-
livering patient education, supervising and instructing
neuromuscular exercise and the use of the GLA:D
registry. On successful completion of the course, the
physiotherapist has access to a digital ‘tool box’ with
everything needed to start GLA:D at his/her clinic,
municipality, or hospital, including access to an on-
line platform with manuals, Power Point presentations
for use in patient education, and other relevant ma-
terial for startup. This ensures that the trained phys-
iotherapists will be able to deliver similar care in
accordance with clinical guidelines across the country.
Additional treatments are permitted, if the physiother-
apist finds them relevant for the individual patient.
Information on if and what additional treatments
were given is however not recorded in the registry.
Education and exercise for patients
GLA:D for patients comprises a ‘minimal intervention’
with three sessions of patient education delivered over
2 weeks and 12 sessions of supervised neuromuscular
exercise delivered twice weekly for 6 weeks (Fig. 1). The
patient education consists of two sessions given by a
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trained physiotherapist and one session led by a previous
participant in GLA:D (‘expert patient’). The sessions
provided by the physiotherapist focus on giving the pa-
tient knowledge of OA and treatment of OA with a par-
ticular focus on exercise, its beneficial effects on
symptoms and general health, and self-help advice. The
third session is intended to give the patients the possibil-
ity to identify themselves with an expert patient, who
has achieved significant improvements in his/her symp-
toms following GLA:D. All three sessions focus on en-
gaging the patients actively and sharing experiences with
each other. Moreover, the patients are strongly encour-
aged to participate in the group-based NEuroMuscular
Exercise programme (NEMEX) [18–22] with 12 sessions
each lasting for 60 min. The GLA:D-trained physio-
therapists supervise the groups, typically comprising
6–12 patients. Patients who for some reason do not
wish to, or are not able to, participate in the super-
vised exercise can do the exercise programme at
home based on detailed instructions by their physio-
therapist or combine supervised and home-based ex-
ercise. After the 8-week programme, the patient is
encouraged to continue being physically active and to
exercise, either with their physiotherapist or in their
local community, to sustain the effects from the treat-
ment in the long term. Individual strategies for the
continuation of physical activity and exercise are dis-
cussed at the 3-month follow-up.
The national GLA:D registry
Data from baseline, 3 and 12 months are registered in
the national, electronic GLA:D registry. Data are object-
ively measured, therapist-reported and patient-reported.
The registry is designed to describe the population at
baseline, and, after the programme of education and ex-
ercise, to evaluate the outcomes of pain, function, quality
of life and other outcomes at 3 and 12 months follow
up. The outcomes assessed are listed in Tables 1 and 2.
The registry contains a core set of outcomes that have
been part of the registry since its initiation. Outcomes
that are relevant for the patient population (based on
emerging evidence) are added, and questions that are no
longer relevant are removed. The registry is continu-
ously improved by user involvement meaning that the
physiotherapists and patients have influence on database
structure, content and questions. Furthermore, data
can be made available for the individual therapists and
patients with the potential of benchmarking their own
results and as motivation for further improvement. A
report, outlining the descriptive results, is made pub-
licly available annually, starting in 2013 [15]. Addition-
ally, it is possible to integrate data from the registry
with data from the Danish Knee Arthroplasty Registry
and the Danish Hip Arthroplasty Registry, among
other registries, which offers a unique opportunity to
evaluate and improve clinical pathways in this patient
population.
Fig. 1 Flow diagram in Good Life with osteoArthritis in Denmark (GLA:D™). Minimal intervention involving education and supervised exercise are
mandatory elements of the GLA:D treatment package
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Patients
In Denmark, patients with OA are typically referred to
the physiotherapist by their general practitioner in which
case approx. 40% of the treatment cost is reimbursed.
Patients can also refer themselves directly to the physio-
therapist but then have to pay the full treatment cost. Fi-
nally, patients can be referred by an orthopaedic surgeon
in which case the full treatment cost is reimbursed. Par-
ticipants may have entered the GLA:D program by all
three means. The treating physiotherapist evaluated the
inclusion and exclusion criteria. The inclusion criteria
for GLA:D are ‘Joint problems from knee and/or hip that
have resulted in contact with the health care system’.
The exclusion criteria are: another reason than OA for
the problems, for example, tumour; inflammatory joint
disease, or sequelae after hip fracture; other symptoms
that are more pronounced than the OA problems, for
example, chronic, generalised pain, or fibromyalgia.
Radiographs are not needed to diagnose OA according
to international [23] and Danish [24] guidelines, and
therefore not part of the eligibility criteria for GLA:D.
Variables
Pain intensity
Mean pain intensity during the last month in the most
affected joint was evaluated at baseline, and after 3 and
12 months on a 100 mm visual analogue scale (VAS)
Table 1 Patient-reported outcomes in Good Life with
osteoArthritis in Denmark (GLA:D™) *
Variable Baseline 3-month
follow up
12-month
follow up
Gender X
Age X
Born in Denmark X
Danish citizen X
Comorbidities X
Educational level X
Previous injury X
Smoking X
Live alone/live together with a partner,
family, friends or others
X
Most affected knee/hip joint X X X
Other affected knee/hip joints X X X
Hand/finger problems X X X
Mean pain intensity during the last
month in most affected joint
X X X
Frequency of knee/hip pain
(KOOS/HOOS P1)
X X X
Pain mannequin (patients mark areas of
the body where they have had pain in
the last 24 h)
X X X
Walking problems due to knee/hip X X X
Walking problems due to other reasons X X X
Days a week being physically active for
at least 30 min
X X X
Frequency and duration of exercise X X X
Compared with others of same age,
personal level of physical activity
X X X
UCLA Activity Score X X X
Fear of movement X X X
Use of pain killers due to knee/hip X X X
Current employment X X X
Sick leave X X X
Home care X X X
SF-12 X X X
EQ-5D X X X
KOOS/HOOS QOL including knee/hip
confidence
X X X
Arthritis Self-Efficacy Scale (subscales:
pain and other symptoms)
X X X
Knee/hip arthroplasty X X X
Desire for surgery of own knee/hip X X X
Satisfaction with GLA:D X X
Frequency of using what was learnt
in GLA:D
X X
*KOOS Knee injury and Osteoarthritis Outcome Score, HOOS Hip disability
and Osteoarthritis Outcome Score, P1 Item 1 from the subscale Pain from
KOOS and HOOS, UCLA Activity Score University of California, Los Angeles
(UCLA) activity score, EQ-5D EuroQol-5 dimension 5 level questionnaire,
QOL The subscale quality of life from KOOS and HOOS
Table 2 Physiotherapist-reported and performance-based
outcomes in Good Life with osteoArthritis in Denmark (GLA:D™)
Variable Baseline 3 months
follow-up
Physiotherapist-reported outcomes
Duration of symptoms X
Prior explanation of knee/hip problems X
Prior treatment of knee/hip problems X
Body Mass Index X X
Most affected knee/hip joint X X
Other affected knee and hip joints X X
Knee and hip surgery X X
X-ray of most affected joint during follow-up
and signs of osteoarthritis on x-ray
X X
Using walking aids X X
On waiting list for surgery X X
Use of painkillers and type X X
Participation in patient education sessions and
number of supervised exercise sessions in GLA:D
X X
Other treatment than GLA:D during follow-up X X
Performance-based outcomes
40-m fast paced walk test X X
30-s chair-stand test X X
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with terminal descriptors of ‘no pain’ (0 mm) and
‘maximum pain’ (100 mm). The VAS is a measure of
pain widely used in patients with OA that is valid, reli-
able and responsive [25].
Intake of painkillers
Intake of painkillers was evaluated by the physiotherapist
asking the patients whether they had taken any joint-
related medication during the last 3 months, at baseline
and after 3 months. If the patients were taking
painkillers, they were asked which type and whether or
not they were taken because of their knee/hip pain
(dichotomised into ‘yes’ or ‘no’ to taking acetaminophen,
nonsteroidal anti-inflammatory drugs (NSAIDs) or
opioids/opioid-like painkillers).
Physical function
Physical function was recorded by the physiothera-
pists and evaluated using the 30-s chair-stand test
and the 40-m fast-paced walk test, which are two
tests recommended by the Osteoarthritis Research
Society International (OARSI) as components of the
minimal core set of performance-based physical func-
tion tests for knee and hip OA [26].
Physical activity
Physical activity was assessed using a question that the
patient answered at baseline, 3 and 12 months about
how many days per week that they were physically active
for at least 30 min. The results were divided into three
groups: physically inactive (0–1 days per week); physic-
ally active but not meeting guideline recommendations
(2–4 days per week); and physically active and meeting
guideline recommendations (5–7 days per week). The
2008 Physical Activity Guidelines Advisory Committee
Report recommends at least 2.5 h of physical activity per
week, because a lower risk of all-cause mortality and a
lower risk of a range of chronic diseases have been con-
sistently observed with this level of physical activity [27].
Joint-related quality of life
Joint-related quality of life was evaluated using the sub-
scale quality of life (QOL) from the self-report question-
naires: the Knee injury and Osteoarthritis Outcome
Score (KOOS) and the Hip disability and Osteoarthritis
Outcome Score (HOOS), with scores ranging from 0
(worst) to 100 (best). KOOS and HOOS are valid, reli-
able and responsive patient-reported outcome measures
previously applied in studies of OA [28–31].
Health care visits and costs for the individual patient
and society
When a sufficient number of patients had been to the
12-month follow up, a health economic evaluation was
conducted. To provide preliminary insight into the ef-
fects of GLA:D on the costs related to OA, the number
of patients on sick leave were used. Sick leave was evalu-
ated at baseline, 3 and 12 months by asking the patient
whether or not they had been on sick leave during the
last year due to their knee or hip joint pain, answered
with a ‘yes’ or a ‘no’.
Access to care across health care sectors and geographic
regions
This was evaluated by 1) reporting the number of
GLA:D units and 2) relating the number of GLA:D units
in the five Regions of Denmark, which had registered
patients in GLA:D indicating active GLA:D units, to the
self-reported number of patients with OA from the
National Health Profile 2013.
Statistical analyses
All patients with data from the 3-month or 12-month
follow ups or a baseline assessment date less than 4 or
13 months before the follow ups were included in the
analyses. A one-month delay of the 3-month and the
12-month follow ups was allowed for pragmatic rea-
sons, based on an expected delay for some patients
due to unforeseen circumstances.
The analyses of pain intensity, KOOS/HOOS QOL,
30-s chair-stand test and the 40-m fast-paced walk test
were conducted using a mixed-effects model (including
all available data points) with the patient as a random ef-
fect and time (baseline, 3 months; or baseline and
12 months) and joint (knee, hip) as fixed effects. Inter-
action between time and joint was also included in the
model. The analysis was conducted, both unadjusted
and adjusted (baseline scores, gender, age, and Body
Mass Index (BMI)). A sensitivity analysis was conducted
excluding those reporting to have undergone a total joint
replacement during follow-up. The results are presented
as estimated marginal means with 95% confidence inter-
vals (CI). Furthermore, the results for pain intensity and
KOOS/HOOS QOL at baseline, 3 and 12 months are
graphically presented.
Ordinal logistic regression analyses (proportional odds
models) were applied to investigate whether physical ac-
tivity level changed from baseline to 3 months and from
baseline to 12 months. A sensitivity analysis was con-
ducted excluding those reporting to have undergone a
total joint replacement during follow-up. The results are
presented as odds ratios (OR) with 95% confidence
intervals.
The McNemar’s test was used to assess differences in
the number of patients taking painkillers (acetamino-
phen, NSAIDs or opioids/opioid-like painkillers) at base-
line and at 3 months and in the number of patients
being on sick leave at baseline and after 12 months. A
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sensitivity analysis was conducted excluding those
reporting to have undergone a total joint replacement
during follow-up. Furthermore, the risk differences were
calculated. The analyses were conducted for patients
with knee and hip OA separately, as differences between
the two groups were anticipated. For the analyses of sick
leave, only patients associated with the labour market
(excluding old-age pensioners and people on early retire-
ment pension or disability pension) were included. Due
to small numbers, the analysis was conducted with pa-
tients with knee and hip OA combined.
The analyses of differences between patients discon-
tinuing and patients not discontinuing GLA:D were
done using unpaired t-test and Pearson’s Chi-Square
test.
The significance level was set at P < 0.05, and all ana-
lyses were performed in IBM SPSS Statistics (Version
22, IBM Corporation, Armonk, NY, USA).
Results
Baseline characteristics of the 9,825 participants with knee
and hip OA included in GLA:D between January 31, 2013
and December 31, 2015 are presented in Table 3.
Completeness of GLA:D registry
Nine hundred and thirty-one patients (9%) who had data
registered at baseline decided to discontinue the GLA:D
programme within the 12 month period, some before ever
starting the programme, others during the programme
and finally some between the 3 and 12 months follow-ups.
The most common reasons for discontinuation were: did
not wish to participate after all (23%), could not attend or
manage to participate in the treatment (16%), decided to
seek other treatment (15%), and could not participate due
to own or family illness (14%). The average age (SD) of
the patients who discontinued was 64.9 (11.1) and 73%
were women. Seventy four percent reported the knee as
their primary problem and 52% of the patients who dis-
continued reported no more than short-term higher edu-
cation as their highest level of completed education.
Average pain (SD) prior to GLA:D for those who discon-
tinued was 52.8 (22.8) for patients with hip OA and 51.6
(23.0) for patients with knee OA, while average BMI was
27.3 (4.4) for patients with hip OA and 28.9 (5.7) for pa-
tients with knee OA. While there were no significant dif-
ference between patients discontinuing and patients not
discontinuing GLA:D in age, proportion of women and
proportion reporting the knee as their primary prob-
lem (P = 0.13–0.89), patients discontinuing had lower
levels of completed education, more pain and higher
BMI (P = 0.001–0.04).
Thus, 8,894 (91%) underwent the GLA:D programme
and were eligible for follow up. Out of those eligible for
follow up, 84% attended the 3-month follow up and 68%
the 12-month follow up. Data from baseline, 3-month
and 12-month follow ups were available for 65%.
Treatment-related variables
Ninety per cent of the patients participated in the first
patient education sessions, and 87% in the second. Only
18% participated in the third patient education session
run by an expert patient, primarily owing to the fact that
several new GLA:D units still had not found an expert
patient to run this session as they had only recently fin-
ished their first group of GLA:D patients. Eighty-three
per cent of the patients with knee OA and 84% of the
patients with hip OA participated in at least 10 super-
vised exercise sessions, while only 4% of the patients
with knee OA and 3% of the patients with hip OA chose
not to participate in the supervised group-based exercise
at all. During the 12-month follow up, 15% of the pa-
tients with hip OA and 5% of the patients with knee OA
had undergone a total joint replacement of their most
affected joint, while 3% of the patients with hip OA and
2% of the patients with knee OA had undergone a total
joint replacement of another hip or knee joint.
Pain intensity
From baseline to 3 months, the patients (n = 7,247) re-
ported a crude mean improvement (95% CI) of 12.4 mm
(11.8 to 13.1) and a similar adjusted (n = 7,189) mean
improvement (95% CI) of 12.4 mm (11.8 to 13.1) in pain
intensity. Including only data from patients who had not
undergone a total joint replacement (n = 7,116), the
adjusted mean improvement (95% CI) was 12.3 mm
(11.7 to 13.0). In all three analyses, a significant inter-
action was demonstrated between follow-up time and
joint (P < 0.001) with larger improvements from baseline
to 3 months in patients with knee OA compared with
patients with hip OA. In the adjusted analysis of all pa-
tients, the patients with knee OA improved (95% CI)
from 48.1 mm (47.5 to 48.7) to 34.3 mm (33.6 to 34.9),
while the patients with hip OA improved (95% CI) from
47.1 mm (46.1 to 48.1) to 36.1 mm (35.0 to 37.1).
From baseline to 12 months, the patients (n = 3,431)
reported a crude mean improvement (95% CI) of
13.7 mm (12.6 to 14.9) and a similar adjusted (n = 3,402)
mean improvement (95% CI) of 13.7 mm (12.6 to 14.9)
in pain intensity. Including only data from patients who
had not undergone a total joint replacement (n = 3,210),
the adjusted mean improvement (95% CI) was 12.0 mm
(10.8 to 13.2).
Only in the analysis without patients who had under-
gone a total joint replacement was a significant inter-
action demonstrated between follow-up time and joint
(P = 0.03) with larger improvements from baseline to
12 months in patients with knee OA compared with pa-
tients with hip OA. In this analysis, the patients with
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knee OA improved (95% CI) from 47.3 mm (46.4 to
48.1) to 33.9 mm (32.7 to 35.0) while the patients with
hip OA improved (95% CI) from 46.3 mm (44.8 to 47.8)
to 35.6 mm (33.7 to 37.6).
Figure 2 illustrates the improvements in pain intensity
from baseline to 3 and 12 months when including all pa-
tients in an adjusted analysis.
Intake of painkillers
Patients with knee OA
From baseline to 3 months (n = 4,023), significantly
fewer patients with knee OA took acetaminophen,
NSAIDs or opioids/opioid-like painkillers (P < 0.0001)
with a risk of taking painkillers (95% CI) of 55.9% (54.4–
57.5) at baseline and 36.7% (35.2–28.2) at 3 months, cor-
responding to a risk reduction of 19.2%. This remained
significant (P < 0.0001; n = 3 994) when excluding those
who had undergone a total knee replacement with a simi-
lar risk of taking painkillers (95% CI) of 55.9% (54.4–57.5)
at baseline and 41.5% (40.0–43.1) at 3 months, corre-
sponding to a risk reduction of 19.3% (Table 4).
Patients with hip OA
From baseline to 3 months (n = 1,385), significantly fewer
patients with hip OA took acetaminophen, NSAIDs or
opioids/opioid-like painkillers (P < 0.0001) with a risk of
taking painkillers (95% CI) of 58.1% (55.5–60.7) at baseline
and 44.7% (42.1–47.3) at 3 months, corresponding to
a risk reduction of 13.4%. This remained significant
(P < 0.0001; n = 1,361) when excluding those who had
undergone a total knee replacement with a risk of taking
painkillers (95% CI) of 57.8% (55.2–60.5) at baseline and
44.5% (41.8–47.1) at 3 months, corresponding to a risk re-
duction of 13.4% (Table 4).
The number of patients taking/not taking painkillers
at baseline and 3 months are presented in Table 4.
Objectively assessed physical function
30-second chair-stand test
From baseline to 3 months, patients (n = 7,537) had a
crude mean improvement (95% CI) of 2.3 (2.2 to 2.4)
and a similar adjusted (n = 7,433) mean improvement
(95% CI) of 2.3 (2.2 to 2.4) chair-stands during 30 s. In-
cluding only patients who had not undergone a total
Table 3 Baseline characteristics in Good Life with osteoArthritis in Denmark (GLA:D™)a
Variable Knee (n = 7 333) Hip (n = 2 492)
Women, n (%) 5 405 (74) 1 840 (74)
Age, mean (SD; range) in years 64.0 (9.9; 18–94) 65.5 (9.7; 15–91)
Body mass index, mean (SD; range) 28.4 (5.2; 15–54) 26.7 (4.6; 14–48)
Highest education level completed: Short-term higher education or lower, n (%) 3 206 (48.5) 1 113 (48.3)
Pain intensity during the last month on a 0–100 mm visual analogue scale, mean (SD) 48.2 (22.0) 47.1 (21.8)
Duration of pain, mean (SD) in months 54.7 (79.8) 40.5 (54.4)
Patients using pain medication (acetaminophen, NSAIDs or opioids/opioid-like painkillers) due to their
joint pain during the last 3 months, n (%)
4 086 (56) 1 478 (59)
30-s chair-stand test, mean number of chair-stands (SD) during 30 s 12.1 (3.7) 12.5 (3.9)
40-m fast-paced walk test, mean (SD) time to complete 40 m in seconds. 28.7 (8.8) 28.7 (8.9)
Patients self-reporting being physically active for at least 30 min at least 5 days a week, n (%) 3 976 (60) 1 443 (63)
Joint-related quality of life, from the KOOS/HOOS quality of life subscale, 0–100, worst to best, mean (SD) 44.9 (14.5) 47.3 (14.9)
Patients on sick leave during the last 12 months because of their joint pain, n (%) 686 (27) 132 (18)
aKOOS Knee injury and Osteoarthritis Outcome Score, HOOS Hip disability and Osteoarthritis Outcome Score; the analyses of educational level included 6 613
patients with knee OA and 2 303 patients with hip OA. The analyses of patients on sick leave included only patients with knee (n = 2,531) and hip OA (n = 736)
associated with the labour market (excluding old-age pensioners and people on early retirement pension or disability pension)
Fig. 2 Pain intensity at baseline, 3 and 12 months in patients with
knee and hip osteoarthritis participating in Good Life with
osteoArthritis in Denmark (GLA:D™). Adjusted (baseline pain
intensity, gender, age, and BMI) estimated marginal means from a
mixed effects model (n = 3,402). Error bars indicate 95% confidence
intervals. Pain intensity was significantly lower at 3 and 12 months
compared with baseline (*; P < 0.001). VAS = Visual Analogue Scale
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joint replacement (n = 7,363), the adjusted mean im-
provement (95% CI) was similar at 2.3 (2.2 to 2.4).
40-metre fast-paced walk test
From baseline to 3 months, patients (n = 7,478) had a
crude mean improvement (95% CI) of 2.5 (2.3 to 2.7)
and a similar adjusted (n = 7,367) mean improvement
(95% CI) of 2.5 (2.3 to 2.7) seconds to complete the
40-m fast-paced walk test. Including only data from
patients who had not undergone total joint replace-
ment (n = 7,297), the adjusted mean improvement
(95% CI) was similar at 2.5 (2.3 to 2.6).
Patient-reported physical activity
The odds of being more physically active at 3 months
compared with that at baseline was 1.18 (1.10 to
1.27), which was significant: P < 0.0001 (n = 7,273).
This remained significant (P < 0.0001; n = 7,199) when
excluding those who had undergone a total joint re-
placement, with identical odds of being more physic-
ally active at 3 months compared with that at
baseline of 1.18 (1.10 to 1.27).
The odds of being more physically active at 12 months
compared with that at baseline was 1.10 (0.99 to 1.23),
which was not significant: P = 0.09 (n = 3,429). This
remained non-significant (P = 0.16; n = 3,235) when ex-
cluding those who had undergone a total joint replace-
ment, with the odds of being more physically active at
12 months compared to that at baseline being 1.08 (0.97
to 1.22).
The percentage of patients being physically inactive
(0–1 days per week with at least 30 min of physical ac-
tivity), physically active but not meeting guideline rec-
ommendations (2–4 days per week), and physically
active and meeting guideline recommendations (5–7
days per week) at baseline compared with that at 3 and
12 months are presented in Table 5.
Joint-related quality of life
From baseline to 3 months, patients (n = 7,258) reported
a crude mean improvement (95% CI) of 5.4 (5.0 to 5.9)
and a similar adjusted (n = 7,206) mean improvement
(95% CI) of 5.4 (5.0 to 5.9) in KOOS/HOOS QOL. In-
cluding only data from patients who had not undergone
a total joint replacement (n = 7,132), the adjusted mean
improvement (95% CI) was similar at 5.4 (4.9 to 5.8). In
all three analyses, a significant interaction was demon-
strated between follow-up time and joint (P < 0.001) with
larger improvements in patients with knee OA com-
pared with patients with hip OA. In the adjusted analysis
of all patients, the patients with knee OA improved
(95% CI) from 44.9 (44.5 to 45.3) to 51.1 (50.7 to 51.6)
units while the patients with hip OA improved (95% CI)
from 47.1 (46.4 to 47.7) to 51.7 (50.9 to 52.5) units on a
0–100 worst to best scale.
From baseline to 12 months, the patients (n = 3,434)
reported a crude mean improvement (95% CI) of 9.4
(8.6 to 10.2) and a similar adjusted (n = 3,401) mean im-
provement (95% CI) of 9.4 (8.6 to 10.2) units in KOOS/
HOOS QOL. Including only data from patients who had
Table 4 Patients taking painkillers and being on sick leave at baseline and follow upa
Baseline to 3 months
Outcome Joint Baseline status Yes at 3 months No at 3 months
Painkillers due to knee/hip? Knee (n = 4,023) Yes at baseline (n = 2,250) 1,162 1,088
No at baseline (n = 1,773) 315 1,458
Risk of taking painkillers at baseline (95% CI) 55.9% (54.4–57.5)
Risk of taking painkillers at 3 months (95% CI) 36.7% (35.2–28.2)
Hip (n = 1,385) Yes at baseline (n = 804) 472 332
No at baseline (n = 581) 147 434
Risk of taking painkillers at baseline (95% CI) 58.1% (55.5–60.7)
Risk of taking painkillers at 3 months (95% CI) 44.7% (42.1–47.3)
Baseline to 12 months
Outcome Joint Baseline status Yes at 12 months No at 12 months
Sick leave due to knee/hip?* Knee and hip (n = 711) Yes at baseline (n = 173) 53 120
No at baseline (n = 538) 53 485
Risk of being at sick leave at baseline (95% CI) 24.3% (21.2–27.5)
Risk of being at sick leave at 12 months (95% CI) 14.9% (12.3–17.5)
a Painkillers were defined as acetaminophen, NSAIDs or opioids/opioid-like painkillers; only patients associated with the labour market (excluding old-age pensioners
and people on early retirement pension or disability pension) were included in the analysis of sick leave. The risk of taking pain killers at 3 months and the risk of being
on sick leave at 12 months were significantly lower than the corresponding risks at baseline (P < 0.0001) for patients with knee and hip OA, respectively
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not undergone a total joint replacement (n = 3,208),
the adjusted mean improvement (95% CI) was 8.2
(7.3 to 9.0).
Figure 3 illustrates the improvements in KOOS/HOOS
QOL from baseline to 3 and 12 months when including
all patients in an adjusted analysis.
Patient-reported sick leave
From baseline to 12 months (n = 711), significantly fewer
patients were on sick leave (P < 0.0001) compared with
the year prior to their participation in GLA:D. The risk
of being on sick leave (95% CI) was 24.3% (21.2–27.5) at
baseline and 14.9% (12.3–17.5) at 12 months, corre-
sponding to a risk reduction of 9.4%. This remained sig-
nificant (P < 0.0001; n = 623) when excluding those who
had undergone a total joint replacement, with a risk of
being on sick leave (95% CI) of 24.3% (21.0–27.6) at
baseline and 9.8% (7.5–12.1) at 12 months, correspond-
ing to a risk reduction of 14.5% (Table 4).
The number of patients being on sick leave at baseline
compared with that at 12 months are presented in
Table 4.
Access to care across health care sectors and geographic
regions
In the second quarter of 2016, there were 4.7 million cit-
izens who were 16 years or older in Denmark [32].
Based on percentages of patients with self-reported OA
(not restricted to knee and hip OA) from the National
Health Profile 2013 [33], 932,563 citizens of 16 years
and above have OA in Denmark.
As of May 2016, there were 286 active GLA:D units
across Denmark, which had registered patients in
GLA:D, suggesting a patient to clinic ratio of 3,229 citi-
zens with self-reported OA per GLA:D unit in Denmark.
Figure 4 illustrates the distribution of active GLA:D
units across the five regions of Denmark and the num-
ber of citizens of 16 years and above with self-reported
OA per GLA:D unit. The number of GLA:D units has
increased exponentially each year since 2013.
The most active GLA:D units are private physiother-
apy clinics (n = 257), where patients pay 60-100% of the
treatment cost. Only 20 municipalities (with 26 GLA:D
units) of the 98 Danish municipalities offering physio-
therapy treatment free of charge to the patient (20%)
have registered patients in GLA:D (physiotherapists
Table 5 Patient physical activity levels at baseline and follow-upa
Baseline to 3 months (n = 7,273)
Physical activity level Percentage at baseline Percentage at 3 months
Physically inactive 8.1% 3.8%
Physically active but not meeting guideline recommendations 30.6% 32.4%
Physically active and meeting guideline recommendations 61.3% 63.8%
Odds of being more physically active at 3 months compared to at baseline (95% CI) 1.18 (1.10 to 1.27)
Baseline to 12 months (n = 3,429)
Outcome Percentage at baseline Percentage at 12 months
Physically inactive 8.2% 4.3%
Physically active but not meeting guideline recommendations 29.8% 32.7%
Physically active and meeting guideline recommendations 62.1% 63.0%
Odds of being more physically active at 12 months compared to at baseline (95% CI) 1.10 (0.99 to 1.23)
a The proportion of patients being physically inactive (0–1 days per week with at least 30 min of physical activity), physically active but not meeting guideline
recommendations (2–4 days per week), and physically active and meeting guideline recommendations (5–7 days per week)
Fig. 3 Joint-related quality of life (KOOS/HOOS QOL) at baseline, 3
and 12 months in patients with knee and hip osteoarthritis
participating in Good Life with osteoArthritis in Denmark (GLA:D™).
Adjusted (baseline KOOS/HOOS QOL, gender, age, and BMI)
estimated marginal means from a mixed effects model (n = 3,405).
Error bars indicate 95% confidence intervals. QOL was significantly
higher at 3 and 12 months compared with baseline (*; P < 0.001)
and at 12 months compared with 3 months (#; P < 0.001). KOOS = Knee
injury and Osteoarthritis Outcome Score; HOOS = Hip disability and
Osteoarthritis Outcome Score
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from 32 municipalities have been on the GLA:D course).
The last active GLA:D units are two at private hospitals,
most often paid by either the government or a private
health insurance, and one GLA:D unit based at a public
hospital.
Discussion
Patients with knee and hip OA participating in educa-
tion and supervised exercise delivered nationwide in
clinical practice experience improved pain, physical
function, physical activity (only in the short term) and
quality of life in the short term and long term as
compared to before participating in the treatment
programme. Furthermore, fewer patients were taking
painkillers after the treatment as compared with before,
and fewer patients were on sick leave 12 months after
the treatment as compared with before the treatment.
Albeit the treatment is offered in all five health care
regions of Denmark, the uptake in the Danish muni-
cipalities, where the program is free of cost to the
participant, is still low. This suggests there is room
for improvement to ensure that all patients, including
those who potentially do not participate due to a fi-
nancial barrier, are offered evidence-based care for
osteoarthritis.
Exercise is feasible and effective in patients at all sever-
ity levels of OA [34], even in those with moderate to se-
vere OA eligible for total knee and total hip replacement
[20–22, 35]. Furthermore, if the patient progresses to
surgery, supervised exercise prior to surgery seems ap-
propriate since it is associated with a faster post-
operative recovery [36]. In two recent systematic reviews
and meta-analyses of 54 randomised controlled trials of
exercise in patients with knee OA [10] and 10 in pa-
tients with hip OA [11], exercise was demonstrated to
reduce pain and improve function and quality of life in
patients with knee OA, but not in patients with hip OA,
immediately after the treatment. The treatment effects
were sustained for least 2 to 6 months after the treat-
ment period [10, 11]. Although without a control group
for comparison, our study confirms these findings from
randomized controlled trials can be transferred into
real-life clinical practice. We found that education and
exercise delivered through GLA:D improved pain by
13.8 points for patients with knee OA and 11.0 points
for patients with hip OA immediately after the treat-
ment, while joint-related quality of life improved by 6.2
points in the patients with knee OA and 4.6 points in
the patients with hip OA. Furthermore, the effects trans-
lated into objectively measureable positive effects in gait
Fig. 4 Distribution of clinical units in Good Life with osteoArthritis in Denmark (GLA:D™). The GLA:D units across the five regions of Denmark,
which had registered patients in the GLA:D registry, and the number of citizens of 16 years and above with self-reported osteoarthritis (OA) per
GLA:D unit. Picture of Denmark has been modified from Jarke [45] licensed under the Creative Commons Attribution-Share Alike 2.5 Generic License
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speed and ability to transfer from sitting to standing,
while only a small, immediate, self-reported effect on
physically activity level was demonstrated. We found
that the effects seen immediately after GLA:D were sus-
tained or even further improved at 12 months compared
with 3 months. We speculate that the educational ses-
sions are a key component to the sustained results
9 months after the treatment programme ended, as par-
ticipants learn about the disease, how to self-manage,
and the importance of life-long exercise and physical ac-
tivity for sustained effects. Furthermore, the educational
sessions address common misconceptions of exercise be-
ing detrimental to the OA joint, and that joints with
more severe radiographic OA severity are less likely to
benefit from exercise. This speculation is supported by a
recent review, highlighting the importance of patient
education in order to improve patient adherence to
exercise [37].
An interesting finding was the reduced risk of taking
painkillers following GLA:D compared with before
GLA:D. Our results confirm similar within-group
findings from two randomised controlled trials where
one treatment arm received a combined treatment
programme including the same exercise and educational
programme as in GLA:D [21, 22]. Since acetaminophen,
NSAIDs and opioids are associated with an increased
risk of serious adverse events [12], while adverse events
related to exercise are uncommon, mild and temporary,
even in patients with moderate to severe OA [18, 38],
our findings hold promise, not only due to the pain-
relieving effects, but also since it has the potential of re-
ducing serious adverse events in the community.
Another promising finding of our study is the reduced
risk of sick leave 1 year after GLA:D compared with be-
fore GLA:D. Patients with knee OA have twice the risk
of being on sick leave and 40–50% increased risk of re-
ceiving a disability pension as compared with the general
population, with approximately 2% of all sick days in the
society being due to knee OA [39]. It is important to
recognize that since we did not include a control group,
we cannot attribute the change in sick leave to the
GLA:D programme. In theory, societal and other
changes may well influence rates of sick leave. However,
the findings are encouraging and suggest that offering a
treatment programme of education and exercise therapy
to all patients with OA may have a huge impact on the
societal burden from osteoarthritis.
As illustrated in Fig. 4, each region of Denmark has a
large number of GLA:D units. However, the number of
potential OA patients per unit varies across the regions
spanning from 2,000 citizens to 4,179 citizens. Whether
an optimal number of citizens per unit exists is uncer-
tain, but the numbers highlight that the availability of
GLA:D is different across the regions. Since the number
of GLA:D units has increased rapidly each year, the
number of patients per unit is expected to be reduced in
the future. However, most of the GLA:D units are pri-
vate, where patients pay most of the treatment costs
themselves, while only one in five Danish municipalities
are offering GLA:D at no charge to patients. As lower
socio-economic status is associated with an increased
risk of OA [40], and since socio-economic disparities
exist when it comes to accessing treatments including
education and exercise [41], this might also affect the
generalizability of our findings. A future focus for the
Danish municipalities should be to ensure that all pa-
tients have access to GLA:D to overcome potential fi-
nancial barriers to participation.
Some limitations should be mentioned. First of all, the
lack of a control group most probably results in an over-
estimation of the specific treatment effects when com-
pared to the effects seen in controlled clinical trials, as
the contextual effects contributing to the overall treat-
ment effect cannot be determined [42]. The effect per-
ceived by a patient in clinical practice however consists
of both the specific and unspecific treatment effects.
Secondly, a large proportion (62%) of the patients were
already at baseline physically active at least 30 min per
day 5 days a week, which is somewhat higher than pre-
sented in a systematic review demonstrating that in
other countries 41% of patients with knee OA and 58%
with hip OA complete at least 150 min. of moderate to
vigorous physical activity a week [43]. Danish partici-
pants being more physically active already at baseline
could be part of the explanation for the small and only
short-term improvement in physical activity seen. It
should also be noted that we used self-report of physical
activity which is known to be difficult and biased [44].
Thirdly, patients discontinuing GLA:D had lower levels
of completed education, more pain and higher BMI than
patients not discontinuing. Albeit, the differences were
relatively small, this suggests that more attention should
be given to specific subgroups in GLA:D to support
their continuation of the programme. Lastly, the ana-
lyses are based on registry-based data collected in
clinical practice as opposed to the rigorous, controlled
setting of a randomised, controlled trial, thereby
reflecting wider variations in treatment protocols and
data collection procedures for objectively-measured
outcomes. However, the results support implementa-
tion of education and exercise in a real-life clinical
setting to improve the symptoms of patients with
knee and hip OA worldwide.
Conclusions
Education and supervised exercise delivered nationwide
in Denmark in clinical practice through GLA:D ap-
peared to improve pain, physical function, physical
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activity and quality of life and reduce the number of pa-
tients taking painkillers and being on sick leave. As
GLA:D includes structured, supervised exercise and ad-
vice on physical activity, it has the potential to not only
improve OA symptoms, but also to positively affect
other chronic diseases and improve the general health
and well-being of Danish citizens.
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